SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Spero Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.12+0.02 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $64.92M
- P/E (TTM)
- 28.0
- Dividend yield
- –
Share price
−$1.09 (−49.32%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Spero Therapeutics, Inc. saw revenue fall 3.3% to $47.00M over the twelve months to Jun 30, 2026.
Revenue
$47.00M
-3.3% vs. a year earlier
Operating income
$6.03M
TTM Q2 2026
EPS, diluted
$0.04
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $64.92M
- P/E ratio
- 28.0
- Price to sales
- 1.38
- Price to book
- 1.47
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $47.00M
- Net income
- $7.38M
- EPS, diluted
- $0.04
- Book value per share
- $0.76
- Diluted shares
- 58M
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
$47.00M-3.3% YoY
Operating income
$6.03M
Net income
$7.38M
EPS, diluted
$0.04
Free cash flow
–
Reported periodTrailing twelve months